Sight Sciences, Inc. announced new data from a 12-month retrospective sub-analysis—in partnership with Verana Health—of intraocular pressure (IOP)-lowering medication after using FDA-cleared or approved minimally-invasive glaucoma surgery (MIGS) procedures in glaucoma patients.
Talk about this analysis.
The companies assessed the medical records of 16,789 patients with mild-stage glaucoma using the American Academy of Ophthalmology’s (AAO) Intelligent Research in Sight (IRIS) Registry.
Patients were divided into four separate cohorts based on the type of procedure they received:
- Enabled by the OMNI Surgical System in combo with cataract
- Via the iStent Inject in combo with cataract
- Via the Hydrus in combo with cataract
- Via cataract surgery alone (at pre-specified time intervals up to 24 months)
Back up … talk about this IRIS Registry.
Launched in 2014, the AAO’s IRIS Registry is the first electronic health record-based comprehensive eye disease and condition registry in the United States.
Gotcha. Tell me more about this analysis.
The analysis included a review of real-world clinical outcomes data of MIGS devices and procedures (within the IRIS Registry) from 2018 to 2020, with the primary endpoint being an evaluation and comparison of IOP and medicine reduction among the use of MIGS in combination with cataract surgery among the four cohorts.
So what did this analysis find?
It found that patients in the first cohort (using the OMNI Surgical System) experienced the highest average medication reduction (mean reduction from baseline of 1.01 glaucoma medications at 12-months, postop).
How did this compare to the other cohorts?
The first cohort patients’ medication reduction was a statistically greater medication reduction (p<0.001) versus that noted in cohort 2 (using the iStent inject) and cohort 4 (using cataract surgery alone).
What else?
The analysis noted no statistical significance in the average medication reduction between the Hydrus and OMNI Surgical System.
Significance of this analysis?
According to Paul Badawi, co-founder and CEO of Sight Sciences, “This is the first large-scale comparative study leveraging the IRIS Registry with the most comprehensive MIGS dataset ever assembled using pharmacy claims data to understand glaucoma medication utilization.”
Final thoughts.
Michael Mbagwu, MD, adjunct clinical instructor of Ophthalmology at Stanford University School of Medicine and senior medical director at Verana Health, stated that, based on the data, stakeholders/physicians should “reevaluate treatment paradigms for glaucoma patients—whether it be patients seeking to reduce their daily medication burden, surgeons looking for clinically effective options, or payors interested in cost-effective treatments."